Equities research analysts at BMO Capital Markets lifted their price target on shares of Vitamin Shoppe (NYSE: VSI) to $55.00 in a research note issued to investors on Wednesday. The firm currently has a “market perform” rating on the stock.
A number of other firms have also recently commented on VSI. Analysts at JPMorgan Chase (NYSE: JPM) raised their price target on shares of Vitamin Shoppe from $47.00 to $56.00 in a research note to investors on Wednesday. Separately, analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of Vitamin Shoppe to $54.00 in a research note to investors on Tuesday. Finally, analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of Vitamin Shoppe to $52.00 in a research note to investors on Tuesday, February 28th.
Vitamin Shoppe traded down 1.54% on Wednesday, hitting $53.24. Vitamin Shoppe has a 52-week low of $34.49 and a 52-week high of $54.91. The company has a market cap of $1.561 billion and a price-to-earnings ratio of 31.24.
Vitamin Shoppe last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. The company’s revenue for the quarter was up 14.4% on a year-over-year basis. Analysts expect that Vitamin Shoppe will post $0.44 EPS next quarter.
Vitamin Shoppe, Inc. is a specialty retailer and direct marketer of vitamins, minerals, herbs, specialty supplements, sports nutrition and other health and wellness products.